HK1258394A1 - 治療劑傳遞 - Google Patents

治療劑傳遞

Info

Publication number
HK1258394A1
HK1258394A1 HK19100801.8A HK19100801A HK1258394A1 HK 1258394 A1 HK1258394 A1 HK 1258394A1 HK 19100801 A HK19100801 A HK 19100801A HK 1258394 A1 HK1258394 A1 HK 1258394A1
Authority
HK
Hong Kong
Prior art keywords
delivery
therapeutic agent
therapeutic
agent
Prior art date
Application number
HK19100801.8A
Other languages
English (en)
Inventor
Jan Lötvall
Jonas Andrej Nilsson
Original Assignee
Codiak Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Codiak Biosciences Inc filed Critical Codiak Biosciences Inc
Publication of HK1258394A1 publication Critical patent/HK1258394A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
HK19100801.8A 2012-11-13 2016-03-17 治療劑傳遞 HK1258394A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE1251290 2012-11-13

Publications (1)

Publication Number Publication Date
HK1258394A1 true HK1258394A1 (zh) 2019-11-08

Family

ID=49582755

Family Applications (2)

Application Number Title Priority Date Filing Date
HK16103132.5A HK1216105A1 (zh) 2012-11-13 2016-03-17 治療劑的遞送
HK19100801.8A HK1258394A1 (zh) 2012-11-13 2016-03-17 治療劑傳遞

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK16103132.5A HK1216105A1 (zh) 2012-11-13 2016-03-17 治療劑的遞送

Country Status (8)

Country Link
US (3) US9856477B2 (zh)
EP (2) EP3415627A1 (zh)
JP (3) JP6391582B2 (zh)
CN (1) CN105051192B (zh)
CA (1) CA2930339A1 (zh)
ES (1) ES2686129T3 (zh)
HK (2) HK1216105A1 (zh)
WO (1) WO2014076137A1 (zh)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100183558A1 (en) 2008-10-17 2010-07-22 Zhennan Lai Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules
PL2972193T3 (pl) 2013-03-13 2020-08-24 University Of Miami Sposób izolacji i oczyszczania mikropącherzyków z supernatantów hodowli komórkowej i płynów biologicznych
US9717726B2 (en) 2013-03-14 2017-08-01 Maregade Rx, LLC Product and method for treating diarrhea
WO2014210448A1 (en) * 2013-06-27 2014-12-31 The Board Of Regents Of The University Of Texas System Compositions and methods relating to myomaker-induced muscle cell fusion
WO2016201323A1 (en) 2015-06-10 2016-12-15 Board Of Regents, The University Of Texas System Use of exosomes for the treatment of disease
EP4310500A3 (en) 2016-01-15 2024-04-03 American Gene Technologies International Inc. Methods and compositons for the activation of gamma-delta t-cells
US10767183B2 (en) * 2016-03-09 2020-09-08 American Gene Technologies International Inc. Combination vectors and methods for treating cancer
EP3235908A1 (en) 2016-04-21 2017-10-25 Ecole Normale Superieure De Lyon Methods for selectively modulating the activity of distinct subtypes of cells
AU2017292582C1 (en) 2016-07-08 2021-11-11 American Gene Technologies International Inc. HIV pre-immunization and immunotherapy
WO2018017882A1 (en) 2016-07-21 2018-01-25 American Gene Technologies International Inc. Viral vectors for treating parkinson's disease
JP2020512815A (ja) 2017-04-03 2020-04-30 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド フェニルケトン尿症を処置するための組成物および方法
BR112019023323A2 (pt) 2017-05-08 2020-07-21 Flagship Pioneering Innovations V, Inc. composições para facilitar a fusão de membrana e usos das mesmas
WO2019191444A1 (en) * 2018-03-28 2019-10-03 Board Of Regents, The University Of Texas System Use of exosomes for targeted delivery of therapeutic agents
CN112272706A (zh) 2018-02-17 2021-01-26 旗舰先锋创新V股份有限公司 用于膜蛋白递送的组合物和方法
JP2022506515A (ja) 2018-11-05 2022-01-17 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド 制御性ｒｎａを発現させるためのベクターシステム
CA3120093A1 (en) 2018-11-14 2020-05-22 Flagship Pioneering Innovations V, Inc. Compositions and methods for compartment-specific cargo delivery
CN114207110A (zh) * 2019-03-28 2022-03-18 Agex治疗公司 使用细胞外囊泡诱导的组织再生
EP4013875A1 (en) * 2019-08-14 2022-06-22 Codiak BioSciences, Inc. Extracellular vesicles with stat3-antisense oligonucleotides
EP4025698A1 (en) 2019-09-03 2022-07-13 Sana Biotechnology, Inc. Cd24-associated particles and related methods and uses thereof
CN115443124A (zh) 2020-02-05 2022-12-06 戴尔戴莫生物医疗有限公司 人工突触
WO2021202604A1 (en) 2020-03-31 2021-10-07 Sana Biotechnology, Inc. Targeted lipid particles and compositions and uses thereof
WO2021223659A1 (en) * 2020-05-06 2021-11-11 Nanjing Iaso Biotherapeutics Co., Ltd. Extracellular vesicles targeting cancer cells and uses thereof
CN114716548A (zh) 2021-01-05 2022-07-08 (株)爱恩德生物 抗-fgfr3抗体及其用途
AU2022253020A1 (en) 2021-04-08 2023-10-26 Shirisha AMATYA Cd8-specific antibody constructs and compositions thereof
CN113262212A (zh) * 2021-04-26 2021-08-17 北京大学口腔医学院 一种靶向炎症区域的细胞膜微囊泡及其应用
AU2022280957A1 (en) 2021-05-28 2023-11-30 Sana Biotechnology, Inc. Lipid particles containing a truncated baboon endogenous retrovirus (baev) envelope glycoprotein and related methods and uses
WO2024044655A1 (en) 2022-08-24 2024-02-29 Sana Biotechnology, Inc. Delivery of heterologous proteins
WO2024064838A1 (en) 2022-09-21 2024-03-28 Sana Biotechnology, Inc. Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
WO2024081820A1 (en) 2022-10-13 2024-04-18 Sana Biotechnology, Inc. Viral particles targeting hematopoietic stem cells

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ308053B6 (cs) * 2000-12-01 2019-11-27 Max Planck Gesellschaft Izolovaná molekula dvouřetězcové RNA, způsob její výroby a její použití
US20050159378A1 (en) * 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA)
WO2004100987A2 (en) * 2003-05-06 2004-11-25 Regeneron Pharmaceuticals, Inc. Methods of using il-1 antagonists to treat neointimal hyperplasia
US20110190375A1 (en) * 2008-06-11 2011-08-04 Intradigm Corporation Compositions comprising cmyc sirna and methods of use thereof
US20120177574A1 (en) 2009-07-01 2012-07-12 Aeon Medix Inc. Microvesicles derived from nucleated, mammalian cells and use thereof
EP2578236B1 (en) * 2010-05-26 2016-03-30 Micromedmark Biotech Co., Ltd PREPARATION OF MICROVESICLE-siRNA COMPLEXES AND USE THEREOF IN AIDS TREATMENT
CN101869715A (zh) 2010-05-26 2010-10-27 江苏命码生物科技有限公司 载有干扰核糖核酸的细胞微粒子、其制备方法及其应用
WO2011147086A1 (zh) * 2010-05-26 2011-12-01 江苏命码生物科技有限公司 载有干扰核糖核酸的细胞微粒子、其制备方法及其应用
WO2013138427A1 (en) * 2012-03-16 2013-09-19 The General Hospital Corporation Microvesicle-mediated delivery of therapeutic molecules

Also Published As

Publication number Publication date
WO2014076137A1 (en) 2014-05-22
EP3415627A1 (en) 2018-12-19
US10370663B2 (en) 2019-08-06
ES2686129T3 (es) 2018-10-16
EP2920306B1 (en) 2018-06-27
US20180135056A1 (en) 2018-05-17
JP2019006792A (ja) 2019-01-17
US9856477B2 (en) 2018-01-02
CN105051192B (zh) 2020-04-17
JP2020114258A (ja) 2020-07-30
US20160168572A1 (en) 2016-06-16
CA2930339A1 (en) 2014-05-22
US20200063138A1 (en) 2020-02-27
EP2920306A1 (en) 2015-09-23
CN105051192A (zh) 2015-11-11
JP2016502404A (ja) 2016-01-28
HK1216105A1 (zh) 2016-10-14
JP6391582B2 (ja) 2018-09-19

Similar Documents

Publication Publication Date Title
HK1216105A1 (zh) 治療劑的遞送
HRP20181855T1 (hr) Lipidi za formulacije namijenjene unosu terapijskog sredstva
HK1205461A1 (zh) 用於眼部傳輸治療劑的組合物和方法
IL239557B (en) Microarray for providing therapeutic material and methods for use
HK1201483A1 (zh) 用於定向輸送治療用植入物的設備
GB201212513D0 (en) Therapeutic agents
HK1206620A1 (zh) 血脂異常症治療劑
HK1202826A1 (zh) 藥物輸送裝置
HK1210271A1 (zh) 用於遞送助益劑的眼用裝置
GB201217704D0 (en) Therapeutic agents
HK1202827A1 (zh) 改進型藥物輸送裝置
EP2821073A4 (en) CIRCADIAN RHYTHM IMPROVEMENT AGENT
GB201104632D0 (en) Use of medicament
GB201223021D0 (en) Therapeutic agents
GB201212512D0 (en) Therapeutic agents
GB201210233D0 (en) Therapeutic agents
GB201214985D0 (en) Modified therapeutic agents
GB201213712D0 (en) Modified therapeutic agents